Healthcare >> Analyst Interviews >> November 14, 2011
Big Pharma Moves Toward Orphan Drugs & Emerging Markets – Damien Conover – Morningstar, Inc.
Damien Conover, CFA, is the Editor of Morningstar's Healthcare Observer as well as an Equities Strategist for Morningstar, Inc. He has been covering the health care industry for nearly a decade with a focus on pharmaceutical and biotechnology companies. Before joining Morningstar in 2007, he held Equity Analyst positions at Raymond James Financial Inc., Bank of Montreal and Tucker Anthony. Mr. Conover is a recognized authority in health care investing, appearing regularly on Bloomberg TV, CNBC and CNN. He holds a bachelor's and master's degrees in finance from the University of Wisconsin, where he was a member of the Applied Security Analysis Program. Profile
TWST: What do you cover in the pharma area?
Mr. Conover: My specific coverage is the large pharmaceutical firms, including some of the diversified firms like Abbott (ABT) and J&J (JNJ) as well as